

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 31 of March 2022

	31.03.2022	31.12.2021
	<i>BGN'000</i>	<i>BGN'000</i>
ASSETS		
Non-current assets		
Property, plant and equipment	36 945	38 071
Intangible assets	3 893	3 451
Investments in subsidiaries	19	19
Trade receivables	5 276	5 276
Total non-current assets	46 133	46 817
Current assets		
Inventories	8 616	11 342
Trade and other receivables	62 164	59 220
Current corporate income tax	40	40
Cash and cash equivalents	48	40
Total current assets	70 868	70 642
Total assets	117 001	117 459
LIABILITIES		
Equity		
Share capital	84 500	84 500
Reserves	12 382	12 382
Retained earnings	3 817	1 940
Total	100 699	98 822
Non-current liabilities		
Long-term loans	1 609	1 717
Deferred tax liabilities	1 030	1 030
Retirement benefit obligations	151	151
Total non-current liabilities	2 790	2 898
Current liabilities		
Trade and other liabilities	2 155	4 720
Short-term loans	9 781	9 781
Current portion of long-term loans	927	990
Current corporate income tax	125	125
Other tax liabilities	524	123
Total current liabilities	13 512	15 739
Total liabilities	16 302	18 637
Total equity and liabilities	117 001	117 459

Date of preparation: 26.04.2022

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 31 of March 2022

	31.03.2022	31.03.2021
	<i>BGN'000</i>	<i>BGN'000</i>
Revenue	12 778	13 386
Other income	54	2
Total income	12 832	13 388
Carrying amount of goods sold	(102)	(147)
Changes in inventories of finished products and work in progress	(560)	332
Materials and services	(7 735)	(7 787)
Personnel expenses	(1 371)	(1 345)
Depreciation / amortisation expenses	(940)	(1 072)
Other expenses	(73)	(199)
Finance income	5	1
Finance costs	(89)	(103)
Total expenses	(10 865)	(10 320)
Profit before taxation	1 967	3 068
Corporate income tax expense	(90)	(14)
Profit/Loss for the period	1 877	3 054
Total comprehensive income for the period	1 877	3 054
Earnings per share / in BGN per 1 share /	0.04	0.02

Date of preparation: 26.04.2022

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 31 of March 2022

	31.03.2022	31.03.2021
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	7 570	8 344
Payments to suppliers of materials, goods and services	(4 498)	(5 954)
Payments to personnel	(1 343)	(1 319)
Foreign exchange gains and losses	(12)	(4)
Payments of interest and dividends	(90)	-
Other proceeds / payments	(1 079)	(495)
Net cash flows	548	572
Cash flows from investing activities		
Payments on non-current assets acquired	(361)	(540)
Net cash flows	(361)	(540)
Cash flows from financial activities		
Proceeds from loans	49	33
Payments on loans	(49)	(33)
Payment of interest, dividends	(49)	(50)
Payments on finance lease	(130)	
Other proceeds/payments from treasury shares	-	1
Net cash flows	(179)	(49)
Change in cash and cash equivalents	8	(17)
Cash and cash equivalents at the beginning of the period	40	45
Cash and cash equivalents at the end of the period	48	28

Date of preparation: 26.04.2022

Sofia

Prepared by:.....

/ P. Moneva /

Executive

Director:.....

/B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 31 of March 2022

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2021	82 200	4 088	7 944	2 904	97 136
Profit/loss for the period				1 399	1 399
Other comprehensive income		287			287
Including from tax effect of the revaluation of property, plant and equipment		(39)			(39)
Total comprehensive income		287		604	593
Issue of shares by the owners					
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves	2 300		63	(2 363)	
Total amount of income and expenses recognised during the period	2 300		63	(2 363)	
Balance as of 31.12.2021	84 500	4 375	8 007	1 940	98 822
Balance as of 01.01.2022	84 500	4 375	8 007	1 940	98 822
Profit/loss for the period				1 877	1 877
Other comprehensive income					
Total comprehensive income				1 877	1 877
Issue of shares by the owners					
Total amount of income and expenses recognised during the period					
Balance as of 31.03.2022	84 500	4 375	8 007	3 817	100 699

Date of preparation: 26.04.2022
Sofia

Prepared by:.....
/P. Moneva/

Executive Director:.....
/B. Georgiev /